Your Yourlocation: Home > Tiotropium bromide(136310-93-5) combined with formoterol

Long-acting anti-cholinergic drugs and LABA combined with inhaled better. VanNoord and colleagues compared the efficacy of three regimens in a randomized, open, placebo-controlled, crossover study. All patients were treated with tiotropium bromide(136310-93-5) monotherapy or tiotropium combined with formoterol once daily or twice daily for 2 weeks after 2 weeks of tiotropium pretreatment. A total of 95 stable COPD patients were followed for 24-hour pulmonary function (FEV1, FVC, and deep inspiratory volume (IC)) at baseline and at the end of 2 weeks after each regimen. The mean FEV1 baseline was 1105 L (38% of the predicted value). There were circadian rhythms of FEV1, FVC, and IC during baseline and throughout the treatment period. The mean FEV1 (0-24 h) was improved by tiotropium bromide(136310-93-5) monotherapy in 0108 L; tiotropium combined with formoterol in 1 treatment per day resulted in an improvement in mean FEV1 of 0116 L; tiotropium combined with formoterol Day 2 treatment can improve the average FEV1 0120L. The addition of formoterol to FEV1, FVC, and IC further improved for more than 12 hours in the morning compared with tiotropium monotherapy. The addition of formoterol in the evening further improved FEV1 for more than 12 hours, but FVC, IC improvement time is less than 12h. Tiotropium monotherapy increased the maximum FEV1 to 0123L (22% of baseline), with tiotropium plus formoterol increasing FEV1 to a maximum of 0139L (37% of baseline). Compared with tiotropium alone, tiotropium combined with formoterol once daily and twice daily reduced the amount of albuterol used during daytime stress. Tiotropium combined with formoterol two treatments also reduced the amount of salbutamol administered at night. The combination of tiotropium and formoterol was well tolerated. Indicating that tiotropium bromide(136310-93-5) once daily in combination with formoterol once daily or twice daily in the treatment of COPD is beneficial in improving airflow obstruction, hyperinflation in resting state, and reducing the amount of salbutamol used in stress.

A prospective, double-blind, randomized, parallel-controlled clinical trial of 1067 patients with COPD was conducted to evaluate the efficacy of ipratropium bromide combined with salbutamol. The results showed that combination therapy was more effective than single drug, that is, FEV1 increased more significantly in patients with acute exacerbations and hospital days to further reduce the number, thereby reducing the medical costs. Combination of these two short-acting drugs is now available, such as combitible (combivent) is salbutamol and ipratropium bromide compound. Different drugs with different results. DπUrzo etc. 172 cases of routine inhaled ipratropium bromide control of COPD patients with poor efficacy, were randomly divided into two groups, one in the conventional inhaled ipratropium bromide based on the addition of formoterol, another group Salbutamol was added to the routine infusion of ipratropium bromide for 3 weeks. The results showed that the improvement of lung function and symptoms was better than the latter.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved